Clinical Trial News and Research

RSS

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors.

9 Jan 2014

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

Emmaus Medical, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of innovative and cost-effective treatments and therapies primarily for rare and orphan diseases, today announced it has completed all patient visits for its Phase 3 clinical trial for the treatment of sickle cell disease. Emmaus expects top-line data from the Phase 3 clinical trial to be available in the first quarter of 2014.

8 Jan 2014

OxThera announces initiation of Oxabact clinical study in Primary Hyperoxaluria

OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.

8 Jan 2014

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Advanced Inhalation Therapies, an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis.

8 Jan 2014

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Insight Genetics, Inc. today announced it has received a new $1.5 million Phase II Small Business Innovation Research contract from the National Cancer Institute.

8 Jan 2014

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today the Company has received approval from the United States Food and Drug Administration (FDA) to commence patient screening of a Phase 2b study of PRO 140, a monoclonal CCR5 antibody, for the treatment of patients with Human Immunodeficiency Virus Type 1.

8 Jan 2014

CROS NT acquires MDSL International

As part of the CROS NT Group global growth strategy, CROS NT Ltd today announced the acquisition of MDSL International - a specialist clinical Contract Research Organization (CRO) providing biometrics services such as Clinical Data Management and Statistical services. The financial details of the transaction remain confidential.

8 Jan 2014

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.

8 Jan 2014

Research highlights potential of newly developed radiopharmaceuticals for imaging melanoma metastases

With low survival rates for patients with metastasized melanoma, accurate staging and effective treatments are critical to extending life. New research published in the Journal of Nuclear Medicine highlights the potential of newly developed radiopharmaceuticals with benzamide for the imaging of metastases and as a targeted systemic therapy.

8 Jan 2014

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency.

7 Jan 2014

Minnesota professor receives Hazelden's Dan Anderson Research Award for hybrid CBT study

Matt G. Kushner, Ph.D., professor of Psychiatry, University of Minnesota (Minneapolis) has earned the latest Dan Anderson Research Award for his study examining the effectiveness of a hybrid cognitive behavioral therapy in the treatment of individuals with co-occurring anxiety disorders and alcohol dependence.

7 Jan 2014

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

CVRx, Inc., a privately held medical device company, today announced findings from a health-economic analysis published in the Journal of Hypertension that indicates Barostim Therapy is a cost-effective treatment option for patients with drug resistant hypertension.

7 Jan 2014

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.

7 Jan 2014

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Horizon Discovery and AstraZeneca have entered into a research, collaboration and license agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets. This deal is the second collaboration between AstraZeneca and Horizon, and follows the announcement in April 2013 of an oncology discovery program to explore Horizon's first-in-class kinase target program, HD-001.

7 Jan 2014

Adocia initiates phase IIa clinical trial of BioChaperone Lispro formulation

Adocia, a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, in particular proteins and oncologic treatments, launches today a phase IIa clinical trial on its ultra-fast acting formulation of insulin Lispro (Humalog, Eli Lilly) using its proprietary technology BioChaperone).

7 Jan 2014

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery identified immune system targets on cancer stem cells - cells from which malignant brain tumors are believed to originate and regenerate - and created an experimental vaccine to attack them.

6 Jan 2014

Tight blood pressure control urged in patients with cardiovascular disease

Intensive antihypertensive treatment to a systolic blood pressure target of 130 mmHg is equally beneficial for patients with and without established cardiovascular disease, research suggests.

6 Jan 2014

Scientists conduct clinical trial to determine silk clothing for treatment of eczema

Three hundred children are being recruited for a clinical trial to establish whether or not specialist silk clothing really does help in the treatment of eczema.

6 Jan 2014

BioLife Solutions announces preliminary revenue of $9 million for 2013

BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical-grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, today announced preliminary revenue of $9.0 million for the full year 2013.

6 Jan 2014

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy.

6 Jan 2014

Clinical Trial News and Research

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

OxThera announces initiation of Oxabact clinical study in Primary Hyperoxaluria

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CROS NT acquires MDSL International

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Research highlights potential of newly developed radiopharmaceuticals for imaging melanoma metastases

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

Minnesota professor receives Hazelden's Dan Anderson Research Award for hybrid CBT study

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Adocia initiates phase IIa clinical trial of BioChaperone Lispro formulation

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

Tight blood pressure control urged in patients with cardiovascular disease

Scientists conduct clinical trial to determine silk clothing for treatment of eczema

BioLife Solutions announces preliminary revenue of $9 million for 2013

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer